LON:OXB Oxford Biomedica (OXB) Share Price, News & Analysis GBX 368 +19.50 (+5.60%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range 342.38▼ 36850-Day Range 296.50▼ 348.5052-Week Range 164.29▼ 460Volume435,796 shsAverage Volume227,561 shsMarket Capitalization£368 millionP/E RatioN/ADividend Yield4.57%Price TargetGBX 410 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesStock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider Trades Get Oxford Biomedica alerts: Email Address Oxford Biomedica MarketRank™ Stock AnalysisAnalyst RatingHold2.33 Rating ScoreUpside/Downside11.4% UpsideGBX 410 Price TargetShort InterestN/ADividend StrengthWeakBased on Four FactorsSustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.38 out of 5 stars 2.2 Analyst's Opinion Consensus RatingOxford Biomedica has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageOxford Biomedica has only been the subject of 1 research reports in the past 90 days.Read more about Oxford Biomedica's stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for OXB. Previous Next 1.7 Dividend Strength Dividend LeadershipOxford Biomedica is a leading dividend payer. It pays a dividend yield of 4.57%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthOxford Biomedica does not have a long track record of dividend growth.Read more about Oxford Biomedica's dividend. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for OXB. Previous Next 0.0 News and Social Media Coverage Search InterestOnly 1 people have searched for OXB on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Oxford Biomedica insiders have not sold or bought any company stock.Percentage Held by Insiders16.18% of the stock of Oxford Biomedica is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions57.85% of the stock of Oxford Biomedica is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Oxford Biomedica's insider trading history. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Oxford Biomedica is -225.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Oxford Biomedica is -225.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOxford Biomedica has a P/B Ratio of 4.84. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street veteran, Eric Fry… This mind-blowing new technology could be bigger than the iPhone.Click here for the full story… About Oxford Biomedica Stock (LON:OXB)Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its s LentiVector platform technology is an advanced lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The Platform segment engages in bioprocessing and process development activities for third parties. The Product segment is involved in the research and development of new gene therapeutic product candidates. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, and adenoviral vectors. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.Read More OXB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OXB Stock News HeadlinesJuly 19, 2024 | finanznachrichten.deOxford BioMedica plc: Oxford Biomedica announces CFO transitionJuly 18, 2024 | americanbankingnews.comOxford Biomedica (LON:OXB) Share Price Crosses Above 200-Day Moving Average of $243.51July 26, 2024 | InvestorPlace (Ad)Breaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street veteran, Eric Fry… This mind-blowing new technology could be bigger than the iPhone.May 28, 2024 | finance.yahoo.comOxford Biomedica (LON:OXB) investors are sitting on a loss of 71% if they invested three years agoMay 28, 2024 | finance.yahoo.comOxford Biomedica (LON:OXB) investors are sitting on a loss of 71% if they invested three years agoMay 23, 2024 | lse.co.ukOxford Biomedica Share ChatMarch 5, 2024 | finanznachrichten.deOxford BioMedica plc: Update to Medium-Term Financial Guidance and 2023 Trading and Notice of Preliminary ResultsMarch 5, 2024 | finance.yahoo.comUpdate to Medium-Term Financial Guidance and 2023 Trading and Notice of Preliminary ResultsJuly 26, 2024 | InvestorPlace (Ad)Breaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street veteran, Eric Fry… This mind-blowing new technology could be bigger than the iPhone.February 5, 2024 | lse.co.ukEnSilica hires new chief financial officer from Oxford BiomedicaJanuary 29, 2024 | finance.yahoo.comOxford Biomedica completes acquisition of ABL EuropeDecember 19, 2023 | finance.yahoo.comOxford Biomedica (LON:OXB) shareholders have endured a 79% loss from investing in the stock three years agoDecember 4, 2023 | msn.comOxford Biomedica inks deal to provide ‘footprint’ in EU marketDecember 4, 2023 | finance.yahoo.comOxford Biomedica signs agreement to acquire ABL Europe from Institut Mérieux, consolidating position as a global pure-play CDMOOctober 22, 2023 | finance.yahoo.comOxford Biomedica's UK£39m Market Cap Fall Books Insider LossesSeptember 22, 2023 | finance.yahoo.comOxford Biomedica First Half 2023 Earnings: Misses ExpectationsSeptember 20, 2023 | finance.yahoo.comOxford BioMedica shares soar as vaccine maker raises earnings guidanceJuly 18, 2023 | finance.yahoo.comOxford Biomedica Implements Sapio Sciences' Electronic Laboratory NotebookSee More Headlines Receive OXB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oxford Biomedica and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:OXB CUSIPN/A CIKN/A Webwww.oxfordbiomedica.co.uk Phone+44-1865-783000FaxN/AEmployees891Year FoundedN/APrice Target and Rating Average Stock Price TargetGBX 410 High Stock Price TargetGBX 740 Low Stock Price TargetGBX 180 Potential Upside/Downside+11.4%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)GBX (1.63) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-157,490,000.00 Net Margins-175.89% Pretax MarginN/A Return on Equity-117.29% Return on Assets-15.08% Debt Debt-to-Equity Ratio143.20 Current Ratio3.19 Quick Ratio1.67 Sales & Book Value Annual Sales£89.54 million Price / Sales4.11 Cash FlowGBX 122.40 per share Price / Cash Flow3.01 Book ValueGBX 76 per share Price / Book4.84Miscellaneous Outstanding Shares100,000,000Free FloatN/AMarket Cap£368 million OptionableNot Optionable Beta0.94 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Stuart Paynter (Age 52)CFO & Director Comp: $832kDr. Frank Mathias (Age 62)CEO & Director Mr. Thierry CournezCOO & Oxford Site HeadDr. James Miskin Ph.D.Chief Quality & Technical OfficerMr. Matthew TreagusChief Information OfficerSophia BolhassanHead of Investor RelationsMs. Natalie Louise Walter (Age 51)General Counsel & Company Secretary Ms. Lisa JamesChief People OfficerDr. Kyriacos Mitrophanous Ph.D.Chief Innovation OfficerMs. Kati HudsonHead of Intellectual Property and ContractsMore ExecutivesKey CompetitorsGenusLON:GNSOxford Nanopore TechnologiesLON:ONTErgomedLON:ERGOSilence TherapeuticsLON:SLNPureTech HealthLON:PRTCView All CompetitorsInsidersMichael HaydenBought 10,000 shares on 11/13/2023Total: £1.93 M ($193.00/share)Dame Kay DaviesBought 1,000 shares on 9/26/2023Total: £291,000.00 ($291.00/share)Roch DoliveuxBought 36,130 shares on 9/20/2023Total: £9.90 M ($274.00/share)View All Insider Transactions OXB Stock Analysis - Frequently Asked Questions How have OXB shares performed this year? Oxford Biomedica's stock was trading at GBX 220 at the beginning of 2024. Since then, OXB shares have increased by 67.3% and is now trading at GBX 368. View the best growth stocks for 2024 here. How do I buy shares of Oxford Biomedica? Shares of OXB stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What other stocks do shareholders of Oxford Biomedica own? Based on aggregate information from My MarketBeat watchlists, some other companies that Oxford Biomedica investors own include EnQuest (ENQ), Petra Diamonds (PDL), Sirius Minerals (SXX), Centamin (CEY), Lloyds Banking Group (LLOY), Oxford Biomedica (OXBDF) and Premier Oil (PMO). This page (LON:OXB) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oxford Biomedica plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Oxford Biomedica With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
